Rocket One Inc. Common Stock (NASDAQ:RKTO) Stock Price Down 4.5% – Should You Sell?

Posted by Brian Himes on Oct 8th, 2026

Shares of Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) fell 4.5% on Wednesday. The company traded as low as $0.6645 and last traded at $0.67. 197,693 shares were traded during trading, a decline of 57% from the average daily volume of 464,941 shares. The stock had previously closed at $0.7014.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wall Street Zen downgraded shares of Rocket One Inc. Common Stock from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 16th. Weiss Ratings raised shares of Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Rocket One Inc. Common Stock presently has an average rating of “Hold” and a consensus price target of $5.00.

View Our Latest Stock Report on RKTO

Rocket One Inc. Common Stock Stock Performance

The firm has a market capitalization of $14.95 million, a P/E ratio of -0.82 and a beta of 0.90. The stock has a fifty day moving average price of $0.74 and a two-hundred day moving average price of $0.84.

Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC increased its holdings in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO – Free Report) by 100.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,000 shares of the company’s stock after acquiring an additional 19,500 shares during the quarter. Lido Advisors LLC owned approximately 0.20% of Rocket One Inc. Common Stock worth $33,000 at the end of the most recent quarter. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

About Rocket One Inc. Common Stock

(Get Free Report)

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.